Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.035 AUD
−42.72 M AUD
0.00 AUD
1.42 B
About IMMUTEP LIMITED
Sector
Industry
CEO
Marc Voigt
Website
Headquarters
Sydney
Founded
1987
ISIN
AU000000IMM6
FIGI
BBG000BLY887
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of IMM is 0.355 AUD — it has increased by 2.90% in the past 24 hours. Watch IMMUTEP LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange IMMUTEP LIMITED stocks are traded under the ticker IMM.
IMM stock has risen by 7.58% compared to the previous week, the month change is a 10.94% rise, over the last year IMMUTEP LIMITED has showed a 6.98% increase.
We've gathered analysts' opinions on IMMUTEP LIMITED future price: according to them, IMM price has a max estimate of 2.00 AUD and a min estimate of 0.70 AUD. Watch IMM chart and read a more detailed IMMUTEP LIMITED stock forecast: see what analysts think of IMMUTEP LIMITED and suggest that you do with its stocks.
IMM stock is 5.00% volatile and has beta coefficient of 1.66. Track IMMUTEP LIMITED stock price on the chart and check out the list of the most volatile stocks — is IMMUTEP LIMITED there?
Today IMMUTEP LIMITED has the market capitalization of 502.18 M, it has decreased by −6.94% over the last week.
Yes, you can track IMMUTEP LIMITED financials in yearly and quarterly reports right on TradingView.
IMMUTEP LIMITED is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
IMM earnings for the last half-year are −0.02 AUD per share, whereas the estimation was −0.02 AUD, resulting in a 4.88% surprise. The estimated earnings for the next half-year are −0.02 AUD per share. See more details about IMMUTEP LIMITED earnings.
IMMUTEP LIMITED revenue for the last half-year amounts to 1.77 M AUD, despite the estimated figure of 2.69 M AUD. In the next half-year revenue is expected to reach 1.42 M AUD.
IMM net income for the last half-year is −21.49 M AUD, while the previous report showed −21.23 M AUD of net income which accounts for −1.23% change. Track more IMMUTEP LIMITED financial stats to get the full picture.
No, IMM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, IMM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IMMUTEP LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IMMUTEP LIMITED technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IMMUTEP LIMITED stock shows the buy signal. See more of IMMUTEP LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.